EWM
SAGE icon

Endurance Wealth Management’s Sage Therapeutics SAGE Stock Holding History

Endurance Wealth Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$51K – 516
2016
Q4 		$51K Buy
+1,000
New +$47.1K 0.01% 265

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
OppenheimerFunds
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Endurance Wealth Management's SAGE Position: Q1 2017 in Review

Endurance Wealth Management sold out of Sage Therapeutics (SAGE) in Q1 2017, closing a stake of 1,000 shares — an estimated $51K sold.

Endurance Wealth Management first reported a position in SAGE in Q4 2016 and held it in 1 quarter. The position peaked at $51K in Q4 2016. 190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

  • Endurance Wealth Management reported no remaining Sage Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Endurance Wealth Management sold 1,000 Sage Therapeutics shares in Q1 2017, an estimated $51K.
  • Endurance Wealth Management first reported a position in Sage Therapeutics in Q4 2016 and held it in 1 quarter.
  • Endurance Wealth Management's Sage Therapeutics position peaked at $51K in Q4 2016.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on Endurance Wealth Management's 13F filing for Q1 2017, filed 5 May 2017.